Apr 4, 2024 07:30AM Trevi Therapeutics to Participate in Upcoming April Events

Mar 20, 2024 04:05PM Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

Apr 11, 2023 04:05PM Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Mar 16, 2023 04:05PM Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Sep 23, 2022 05:52AM Trevi Therapeutics (TRVI) Prices $50M Offering

Sep 22, 2022 11:26PM Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering

Sep 22, 2022 04:01PM Trevi Therapeutics (TRVI) Announces Proposed Public Offering of Common Stock, Warrants

Sep 22, 2022 04:01PM Trevi Therapeutics Announces Proposed Public Offering

Jun 29, 2022 04:14PM Trevi Therapeutics (TRVI) PT Raised to $10 at Needham & Company on Haduvio Data, "Valuation Discounts Potential"

May 13, 2022 05:57AM Needham & Company Reiterates Buy Rating, $8 Price Target on Trevi Therapeutics (TRVI) Ahead of Upcoming Trial Data, "Focus Now Turns to The Ph 2b/3 PRISM Trial"

Apr 11, 2022 08:00AM Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

Apr 7, 2022 08:06AM Trevi Therapeutics (TRVI) Announces $55 Million Private Placement of Common Stock, Warrants

Apr 7, 2022 08:00AM Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market

Apr 5, 2022 04:25PM Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

Mar 22, 2022 07:30AM Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

Mar 18, 2022 06:07AM Needham & Company Reiterates Buy Rating, $8 PT on Trevi Therapeutics (TRVI) Ahead of PRISM Trial Readout

Mar 17, 2022 04:05PM Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update

Mar 15, 2022 07:30AM Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough

Feb 1, 2022 11:43AM Phase 2b/3 PRISM Upcoming Data is Trevi's (TRVI) Most Important Readout, Maintain Buy Into the Analysis - Needham & Company

Jan 6, 2022 01:26PM Trevi Therapeutics' (TRVI) Upcoming PRISM Trial Readout is the Most Important Value-Driver - Needham

Nov 11, 2021 06:47AM Trevi Therapeutics (TRVI) PT Lowered to $8 at Needham & Company

Sep 30, 2021 06:57PM Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market

Aug 13, 2021 06:19AM Trevi Therapeutics (TRVI) PT Lowered to $10 at Needham & Company

Apr 7, 2021 07:30AM Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

Apr 7, 2021 07:30AM Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

Oct 21, 2020 07:05AM Companies with NDRs 10/21

Apr 8, 2020 04:05PM TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE

Apr 8, 2020 04:05PM TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE

Jun 3, 2019 07:12AM Needham & Company Starts Trevi Therapeutics (TRVI) at Buy

May 7, 2019 01:29PM Trevi Therapeutics (TRVL) Prices 5.5M Share IPO at $10/Sh

May 7, 2019 01:22PM Trevi Therapeutics Announces Pricing of Initial Public Offering

May 7, 2019 12:57PM Trevi Therapeutics (TRVI) IPO Opens Modestly Lower